Canakinumab for secondary prevention of atherosclerotic disease

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

(2017) Paul M Ridker et al.   LANCET

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

(2017) John W. Eikelboom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

From C-Reactive Protein to Interleukin-6 to Interleukin-1

(2016) Paul M Ridker   CIRCULATION RESEARCH

Cardiovascular disease in Europe: epidemiological update 2016

(2016) Nick Townsend et al.   EUROPEAN HEART JOURNAL

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

Anti-inflammatory therapies for cardiovascular disease

(2014) P. M. Ridker et al.   EUROPEAN HEART JOURNAL

Inflammation in Atherosclerosis

(2012) Peter Libby   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

(2012) Charles A. Dinarello et al.   NATURE REVIEWS DRUG DISCOVERY

Canakinumab

(2010) Eugen Dhimolea   mAbs